Finance

Lists
Outlook: 40.0% bullish·13.3% bearish
Go to analysis
ABSI:NASDAQ
Absci Corp
$7.58
+1.40%
(+0.11) 1D
$7.78
+2.64% (+0.20)
After hours
Closed: Nov 17, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABSI...
Open
$7.57
High
$7.79
Low
$7.34
Mkt. cap
1.31B
Avg. vol.
4.30M
Volume
4.69M
52-wk high
$12.54
52-wk low
$2.24
EPS
-$0.79
Beta
2.22
Shares outstanding
172.75M
No. of employees
140
Open
$7.57
High
$7.79
Low
$7.34
Mkt. cap
1.31B
Avg. vol.
4.30M
Volume
4.69M
52-wk high
$12.54
52-wk low
$2.24
EPS
-$0.79
Beta
2.22
Shares outstanding
172.75M
No. of employees
140
News stories
From web sources and news partners
About Absci Corp
CEO-
Employees140
Founded2011
HeadquartersVancouver, Washington, United States
SectorHealth Care
IndustryBiotechnology
Websiteabsci.com
Analyst ratings
Based on 9 analysts giving stock ratings to ABSI in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ABSI in the last 3 months.
Highest
Current $7.58
$20.00 (+163.85%)
Average
$15.25 (+101.19%)
Lowest
$11.00 (+45.12%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Maintained
$16.00
+111.1%
11/13/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$14.00
+84.7%
11/13/2026
Andrew Tsai
Jefferies
Buy
Initiated
$14.00
+84.7%
10/29/2026
Scott Schoenhaus
KeyBanc
Buy
Maintained
$20.00
+163.9%
10/16/2026
Unknown Analyst
KeyBanc
Buy
Maintained
$20.00
+163.9%
10/16/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$15.00
+97.9%
10/12/2026
Kambiz Yazdi
BTIG
Buy
Reiterated
$16.00
+111.1%
10/06/2026
Brendan Smith
TD Cowen
Buy
Maintained
-
-
09/30/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$16.00
+111.1%
09/24/2026
Gil Blum
Needham
Buy
Maintained
$11.00
+45.1%
09/23/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
$10.00
+31.9%
08/17/2026
Debanjana Chatterjee
JonesTrading
Buy
Maintained
$13.00
+71.5%
08/12/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
$17.00
+124.3%
07/02/2026
Mani Foroohar
Leerink Partners
Buy
Initiated
$12.00
+58.3%
06/04/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$10.00
+31.9%
05/10/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$0.19 / -$0.20
+3.86%beat
Revenue / Est. (USD)
304.00K / 581.70K
-47.74%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
650.00K
215.00K
318.00K
304.00K
Cost of goods sold
24.65M
19.28M
22.62M
23.57M
Cost of revenue
24.65M
19.28M
22.62M
23.57M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.62M
9.06M
9.16M
9.04M
Operating expense
11.44M
11.79M
11.86M
11.73M
Total operating expenses
36.09M
31.06M
34.48M
35.30M
Operating income
-35.44M
-30.85M
-34.16M
-34.99M
Other non operating income
1.35M
1.28M
990.00K
1.71M
EBT including unusual items
-29.72M
-29.58M
-33.17M
-33.28M
EBT excluding unusual items
-34.12M
-29.58M
-33.17M
-33.28M
Income tax expense
-162.00K
18.00K
40.00K
18.00K
Effective tax rate
0.55%
-0.06%
-0.12%
-0.05%
Other operating expenses
-
-
-
-
Net income
-29.56M
-29.60M
-33.21M
-33.30M
Net profit margin
-4,548.00%
-13,766.98%
-10,443.40%
-10,953.95%
Earnings per share
-0.23
-0.19
-0.21
-0.19
Interest and investment income
-
-
-
-
Interest expense
-29.00K
-18.00K
-2.00K
-2.00K
Net interest expenses
-29.00K
-18.00K
-2.00K
-2.00K
Depreciation and amortization charges
2.83M
2.73M
2.70M
2.69M
EBITDA
-32.61M
-28.12M
-31.46M
-32.31M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps